Amgen drug Sensipar fails to meet trial goal
(Reuters) - Amgen Inc said on Friday a late-stage trial of its drug Sensipar failed to reduce the risk of death and cardiovascular problems in patients with a complication of kidney disease.
The goal of the study was to show a reduction in the risk of death, heart attack, unstable angina or heart failure in patients with chronic kidney disease who were receiving dialysis.
Although patients taking Sensipar experienced fewer events, the results were not statistically significant and the trial did not meet its goal, Amgen said in a statement.
Sensipar is approved to treat secondary hyperparathyroidism, a condition in which the body produces too much parathyroid hormone, a natural substance needed to control the amount of calcium in the blood. It can be a consequence of kidney failure.
Sensipar has been shown to lower calcium levels in the blood of patients who are on long-term dialysis for kidney disease. Amgen hoped to show it reduced death and heart risks.
Amgen's shares fell 22 cents, or 0.3 percent, to $68.88 in early trading on Nasdaq.
(Reporting By Toni Clarke; editing by M.D. Golan)
- U.S. war veteran released by North Korea returns home |
- South Korea expands air defense zone to partially overlap China's |
- Dynasty's Congress party punished in Indian state elections
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- Thai PM proposes referendum on her future as protesters prepare big push
Nelson Mandela: 1918 - 2013
Reuters looks at the life and times of Nelson Mandela, an icon of peace and reconciliation who came to embody the struggle for justice around the world. Video